A case of severe thrombocytopenia after the first exposure to rifampicin
Chinatsu Nakane, Koji Nishimoto, Ei Kishimoto, Kosuke Suzuki, Emiko Nakagawa, Moeko Morikawa, Yurina Murakami, Yoichiro Aoshima, et al. (12 authors)
Respiratory Medicine Case Reports · 2023-01
Abstract
Severe immune thrombocytopenia is a rare side-effect of rifampicin (RFP) and can be life-threatening. Here, we report the case of a 74-year-old male with tuberculous pleurisy who developed severe thrombocytopenia after first exposure to RFP. Platelet count decreased to 1 × 103/μL after 7 days of treatment with RFP, isoniazid, ethambutol, and pyrazinamide. After all the drugs were discontinued, the platelet count recovered. As thrombocytopenia did not occur after re-administration of drugs other than RFP, the patient was diagnosed with RFP-induced thrombocytopenia. Clinicians should be aware that RFP can induce acute and severe thrombocytopenia even without previous exposure to this drug.
MeSH terms
- Medicine
- Pyrazinamide
- Ethambutol
- Rifampicin
- Isoniazid
- Immune thrombocytopenia
- Platelet
- Internal medicine
- Tuberculosis
- Gastroenterology